New pill aims to tame rare, debilitating blood disease
NCT ID NCT06764303
Summary
This study is testing an experimental capsule called NTQ5082 for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disease. The main goal is to see if the pill can safely and effectively raise patients' hemoglobin levels, reduce the need for blood transfusions, and control other disease symptoms. It is a Phase 2 trial involving about 24 participants who have not taken similar complement inhibitor drugs before.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 250033, China
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310012, China
Conditions
Explore the condition pages connected to this study.